Drug Development for Rare Diseases (Chapman & HallCRC Biostatistics Series) 1st Edition by Bo Yang , Yang Song, Yijie Zhou
$45.00
Secure checkout
Instant digital download
PDF document
Document details
- Pages
- 233
- File size
- 9.19 MB
- Format
- Digital PDF
- Course
- Biomedical
- Category
- eBook[PDF]
Sign in or create a free account to continue. Your purchase will be saved in My Downloads.
About this ebook
The book Drug Development for Rare Diseases (Chapman & Hall/CRC Biostatistics Series) 1st Edition, edited by Bo Yang, Yang Song, and Yijie Zhou, provides a comprehensive statistical and strategic overview of therapeutic design for small patient populations. [1, 2, 3]
The primary topics and chapters covered in the book include: [1]
- Introduction to Rare Disease Therapy Development: An foundational overview of the rare disease landscape and the unique framework required for orphan drug development. [1]
- Challenges and Opportunities in Rare Disease Drug Development: Insights into the complexities of clinical development, small sample sizes, and the high unmet needs of patients. [1]
- Regulatory Strategies and Considerations: Evaluating the evolving global regulatory environment, framework requirements, and accelerated approval pathways. [1]
- Clinical Trial Design and Analysis Considerations: Deep-dive into innovative, flexible, and statistically robust trial methodologies tailored specifically for small patient cohorts. [1]
- Use of Real-World Evidence (RWE) to Support Drug Development: Exploring how external data sources, natural history studies, and real-world data (RWD) augment or substitute for traditional randomized clinical trials. [1, 2]
- Clinical Development of Pediatric Programs within Rare Diseases: Specialized approaches for evaluating rare conditions that uniquely manifest in, or require extrapolation for, infants and children. [1, 2, 3]
- Use of Modeling and Simulation: Implementing mechanistic modeling, exposure-response calculations, and virtual simulations to optimize dosage and forecast trial outcomes when physical data is scarce. [1, 2, 3]
- Case Studies of Rare Disease Drug Development: Practical, real-world examples demonstrating how these regulatory strategies and innovative designs have been successfully applied in the industry. [1]
File included
tmpphpqG9cMy
9.19 MB